Browse the evidence

Fibrates (specifically fenofibrate) are effective adjunctive treatments for lowering triglycerides and reducing cardiovascular events in type 2 diabetic patients with high triglycerides and low HDL.

If your triglycerides remain high despite statins and lifestyle changes, ask your doctor about adding fenofibrate. It specifically targets high triglycerides and has been shown to reduce cardiovascular events in diabetic patients, even if it doesn't lower mortality.

Screening for dysglycemia (specifically using OGTT to detect impaired glucose tolerance) in patients with coronary artery disease significantly reduces long-term cardiovascular mortality and major adverse cardiovascular events compared to standard care that relies on fasting glucose or HbA1c alone.

If you have heart disease or are at high risk, ask your doctor for an Oral Glucose Tolerance Test (OGTT), not just a fasting blood sugar or A1c. Standard tests often miss 'Impaired Glucose Tolerance' (IGT), which significantly increases your risk of heart attack and death. Detecting this early allows for treatments (like specific glucose-lowering drugs with heart benefits) that can close the survival gap between diabetic and non-diabetic heart patients.

Completeness of pre-treatment self-monitoring (specifically the number of words and numbers recorded in food logs during a screening run-in period) positively predicts greater 1-year weight loss in individuals undergoing intensive lifestyle intervention for type 2 diabetes.

If you are starting a weight loss program, pay close attention to how thoroughly you record your food and activity during the initial screening or trial period. The effort you put into these records (specifically the detail, measured by words and numbers written) is a strong predictor of how much weight you will lose after one year. Treat this screening task as a practice run for the self-monitoring skills you will need during the actual program.

Licensed weight-lowering pharmacotherapies (GLP-1RAs, naltrexone/bupropion, phentermine/topiramate) improve self-reported physical function, but do not significantly improve objectively measured physical function, cardiorespiratory fitness, or physical activity levels.

If you are using FDA/EMA-approved weight loss medications, expect improvements in how you feel you function in daily life (self-reported physical function). However, do not expect these medications alone to significantly boost your actual exercise capacity, VO2 max, or daily activity levels without dedicated exercise training. The benefits are modest and primarily subjective.

In individuals with overweight or obesity at high risk of type 2 diabetes, a trajectory of weight loss followed by weight regain results in a net loss of fat-free mass (FFM) despite fat mass (FM) returning to baseline levels.

If you are overweight or obese and have experienced a cycle of losing weight and then gaining it back, be aware that your body composition may have worsened even if your weight is back to where it started. Specifically, you may have lost muscle mass (fat-free mass) while regaining fat. To counteract this, prioritize resistance training and adequate protein intake during any future weight loss attempts to preserve muscle, as simply returning to your starting weight does not restore your previous body composition.

A trajectory of weight gain followed by weight loss results in a net gain in fat mass (FM) despite fat-free mass (FFM) returning to baseline levels.

If you have gained weight and then lost it back to your starting weight, your body composition may not be the same as it was before. You may have more fat and less muscle than you did initially. To ensure you are maintaining a healthy body composition, incorporate strength training and monitor body composition metrics, not just total body weight.

Drop-set training on leg extensions produces greater non-uniform hypertrophy in the proximal and mid-rectus femoris compared to traditional training, while yielding equivalent strength gains and no differential hypertrophy in the vastus lateralis.

If your goal is to specifically target the Rectus Femoris (the muscle in the middle of your thigh) using leg extensions, using drop sets (reducing weight after failure) may yield better growth than standard sets. However, do not expect this to make you stronger or grow your Vastus Lateralis (outer thigh) any more than standard training would. For general strength and overall quad size, standard training is equally effective and likely less fatiguing.

Transitioning from a very-low-carbohydrate diet to a high-carbohydrate diet requires several weeks (approximately 5-9 weeks) for full glycemic adaptation, meaning a 3-day preparation period is insufficient for accurate diabetes screening in habitual low-carb dieters.

If you have been eating a very low-carb diet and plan to switch to a higher-carb diet (or undergo a diabetes test), do not expect your blood sugar to stabilize immediately. It can take 5 to 9 weeks for your body to fully adapt to processing carbohydrates again. If you are getting a diabetes screening, inform your doctor about your recent low-carb diet history, as a standard 3-day prep may yield a false positive.

Dual GIP and GLP-1 receptor agonist tirzepatide significantly improves kidney outcomes in adults with type 2 diabetes and increased cardiovascular risk compared to insulin.

If you have Type 2 Diabetes and are at risk for kidney disease, ask your doctor about tirzepatide. It is a once-weekly injection that has been shown to significantly reduce the risk of serious kidney problems compared to insulin, while also helping with blood sugar and weight control. You do not need to adjust the dose even if you have kidney disease.

GLP-1 receptor agonists (specifically tirzepatide and liraglutide) significantly reduce Obstructive Sleep Apnea (OSA) severity, measured by Apnea-Hypopnea Index (AHI), primarily through substantial weight loss, while also providing independent cardiovascular benefits such as reduced vascular inflammation and improved endothelial function.

If you have OSA and obesity, GLP-1 agonists like tirzepatide or liraglutide can significantly reduce your sleep apnea severity (AHI) and improve cardiovascular health, largely by helping you lose weight. While CPAP is still the gold standard for mechanically opening the airway, GLP-1s offer a pharmacological option that also targets inflammation and blood pressure. Expect weekly injections and potential gastrointestinal side effects, which may affect adherence. Discuss with your doctor if you are a candidate, especially if you have Type 2 Diabetes.

GLP-1 receptor agonists (specifically Liraglutide and Semaglutide) promote NASH resolution and reduce hepatic steatosis in patients with T2DM and NAFLD, primarily through weight loss and reduced de novo lipogenesis.

If lifestyle changes alone aren't enough to manage your fatty liver and diabetes, ask your doctor about GLP-1 medications like Liraglutide or Semaglutide. These drugs have been shown to significantly improve liver inflammation and fat content, with Semaglutide showing high rates of NASH resolution. They work by mimicking a gut hormone that helps regulate blood sugar and liver fat production.

Pioglitazone improves NASH resolution and fibrosis stages in patients with T2DM and NAFLD, but its use is limited by side effects such as weight gain and bone fracture risk.

Pioglitazone is a diabetes medication that can also improve liver inflammation and fibrosis in fatty liver disease. However, it can cause weight gain, swelling, and increase the risk of bone fractures. It is generally used when other treatments are not suitable or effective, and the benefits for the liver must be weighed against these risks.

Diet-induced weight loss reduces left ventricular mass (LVM) in adults with overweight or obesity, whereas adding moderate-to-vigorous physical activity (≥150 min/week) to diet-induced weight loss preserves LVM.

If you are overweight or obese, losing weight through diet alone will reduce your heart's muscle mass. However, if you combine that diet with at least 150 minutes of moderate-to-vigorous exercise per week, your heart muscle mass is preserved. Both outcomes may be favorable, but preserving heart mass through exercise might be a beneficial adaptation alongside weight loss.

Higher body mass index (BMI) acts as a causal agent for a broad range of health outcomes, including type 2 diabetes, ischemic heart disease, high blood pressure, and various cancers, as demonstrated by Mendelian randomization studies.

Maintaining a healthy body weight is not just about aesthetics; it is a direct causal factor in preventing serious diseases like heart disease, diabetes, and certain cancers. While BMI is an imperfect measure, keeping it within a healthy range reduces your risk. If you have obesity, lifestyle changes, medical interventions, or in severe cases, surgery, are effective ways to reduce this risk.

Maintaining lower HbA1c levels (<7%) is associated with slower progression of biological aging, as measured by the deficit accumulation frailty index, over an 8-year period in adults with type 2 diabetes.

If you have type 2 diabetes, keeping your average blood sugar (HbA1c) below 7% is linked to slower biological aging and less physical decline over time compared to higher levels. Work with your doctor to achieve this target safely, as it appears to protect your long-term health.

Consistent use of metformin (≥50% of assessments) is independently associated with slower progression of the frailty index in adults with type 2 diabetes, after adjusting for HbA1c and weight loss.

Taking metformin consistently is linked to slower physical decline in people with type 2 diabetes, even after accounting for weight loss and blood sugar levels. Discuss with your doctor if metformin is the right long-term strategy for you.

Bariatric surgery significantly reduces all-cause mortality, disease-specific mortality (cancer, cardiovascular, diabetes), and major adverse cardiovascular events (MACEs) in patients with severe obesity compared to matched non-surgical controls.

For individuals with severe obesity, bariatric surgery is a highly effective intervention for reducing the risk of death from cancer, heart disease, and diabetes, as well as preventing major cardiovascular events. It offers superior long-term outcomes compared to lifestyle changes alone for this population. Patients should discuss these benefits with their healthcare providers to determine if they are candidates.

Regular physical exercise prevents age-related skeletal muscle dysfunction, including loss of strength and mitochondrial capacity, by inducing structural remodeling and metabolic adaptations.

Start or maintain regular physical activity, combining aerobic and resistance exercises, to protect your muscles from age-related decline. This is one of the most effective ways to maintain strength, mitochondrial health, and metabolic function as you age.

A lower n-6 to n-3 PUFA ratio (e.g., 5:1) shifts eicosanoid production toward anti-inflammatory mediators (resolvins, protectins), reducing cardiovascular disease risk, whereas the Western diet's high n-6/n-3 ratio promotes inflammation and atherosclerosis.

To reduce cardiovascular risk, aim to lower your intake of omega-6 fatty acids (common in vegetable oils) relative to omega-3s (from fish or algae). A ratio closer to 5:1 or lower is associated with less inflammation and lower CVD risk compared to the typical Western diet ratio.

GLP-1 receptor agonists for obesity treatment cause significant loss of lean body mass (approximately 20-25% of total weight reduction in men and 10-15% in women) and bone density, particularly when rapid weight loss occurs without structured resistance training.

If you are taking a GLP-1 medication for weight loss, you will likely lose some muscle along with fat. To protect your strength and metabolism, you must engage in resistance training (weight lifting) and ensure you are eating enough protein. This is especially important if you are losing weight quickly.

Low-carbohydrate diets are effective for short-term glycemic control and weight loss in T2DM, but benefits often diminish after 12 months and are largely attributable to weight loss rather than carbohydrate restriction itself.

You can try a low-carb diet (50-100g carbs/day) to improve blood sugar and lose weight in the short term. However, be aware that these benefits often fade after a year, likely because you've lost weight. Ensure you are getting enough fiber and monitoring your cholesterol and kidney health.

Modulating the gut microbiome and its metabolites through diet, pharmaceuticals (e.g., GLP-1 agonists, SGLT2 inhibitors), or microbiota therapies (e.g., probiotics, FMT) improves glycemic control and ameliorates Type 2 Diabetes complications by influencing pancreatic islet function, hepatic metabolism, and systemic inflammation.

To leverage the gut-diabetes connection, prioritize high-fiber diets to boost beneficial bacteria that produce short-chain fatty acids (SCFAs) and GLP-1. If lifestyle changes are insufficient, discuss GLP-1 receptor agonists (like semaglutide) or dual agonists (like tirzepatide) with your doctor, as these medications directly exploit the gut-pancreas axis to lower blood sugar and promote weight loss. Probiotics (specifically strains like Akkermansia muciniphila) may offer modest additional benefits, but they are not a replacement for core therapies.

Targeted pharmacotherapy with MC4R agonists (specifically setmelanotide) is efficacious and safe for reducing body weight and hunger in patients with specific genetic causes of obesity, including POMC deficiency, LEPR deficiency, and Bardet-Biedl syndrome (BBS).

If you have been diagnosed with a specific genetic form of obesity (like POMC, LEPR, or BBS deficiency), ask your doctor about setmelanotide. This targeted drug has shown significant weight loss and hunger reduction in clinical trials for your specific genetic profile, unlike standard diets.

Anti-obesity medications and bariatric surgery improve Obstructive Sleep Apnea (OSA) severity, measured by Apnea-Hypopnea Index (AHI), in direct proportion to the percentage of body weight lost, regardless of the specific intervention type.

If you have OSA and are overweight, losing weight through medication or surgery will improve your sleep apnea severity. For every 1% of body weight you lose, your Apnea-Hypopnea Index (AHI) drops by about 0.45 events per hour. This benefit is consistent whether you lose the weight through medication or surgery, meaning you can choose the method that fits your lifestyle and risk tolerance while expecting similar proportional improvements in your sleep apnea.